Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States

Kidney International

Volumn 65, Issue 5, 2004, Pages 1864-1869

  Li, Shuling ^b   Foley, Robert N ^a   Collins, Allan J ^b  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b NONE

Author keywords

Anemia; Death; Diabetes mellitus; Erythropoietin; Hemoglobin; Hospitalization; Kidney Dialysis Outcomes Quality Initiative (K DOQI); Peritoneal dialysis

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ADULT; AGED; ANEMIA; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED STATES;

EID: 2342520672     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00584.x     Document Type: Conference Paper

References (19)

1. NATIONAL KIDNEY FOUNDATION-DIALYSIS OUTCOMES QUALITY INITIATIVE: NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30:S192-S240, 1997
2. MADORE F, LOWRIE E, BRUGNARA C, et al: Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 8(12):1921-1929, 1997
3. MA J, EBBEN J, XIA H, COLLINS A: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10(3):610-619, 1999
4. COLLINS AJ, LI S, ST.PETER WL, et al: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12:2465-2473, 2001
5. U.S. RENAL DATA SYSTEM: USRDS 2001 Annual Data Report, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
6. XIA H, EBBEN J, MA J, COLLINS A: Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10:1309-1316, 1999
7. COLLINS AJ, LI S, EBBEN J, et al: Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 36(2):282-293, 2000
8. AL AHMAD A, RAND WM, MANJUNATH G, et al: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38:955-962, 2001
9. MCCLELLAN WM, FLANDERS WD, LANGSTON RD, et al: Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admittted to community hospitals: a population-based study. J Am Soc Nephrol 13(7):1928-1936, 2002
10. HORWICH TB, FONAROW GC, HAMILTON MA, et al: Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39(11):1780-1786, 2002
11. SILVERBERG DS, WEXLER D, BLUM M, et al: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35:1737-1744, 2000
12. HOUSE AA, PHAM B, PAGE DE: Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. Nephrol Dial Transplant 13:1763-1769, 1998
13. DUKE M, ABELMANN WH: The hemodynamic response to chronic anemia. Circulation 39:503-515, 1969
14. CANADIAN ERYTHROPOIETIN STUDY GROUP: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300:573-578, 1990
15. SIKOLE A, POLENAKOVIC M, SPIROVSKA V, et al: Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 17:977-984, 1993
16. FOLEY RN, PARFREY PS, MORGAN J, et al: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58:1325-1335, 2000
17. MCMAHON LP, MCKENNA MJ, SANGKABUTRA T, et al: Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol Dial Transplant 14:1182-1187, 1999
18. MCMAHON LP, MASON K, SKINNER SL, et al: Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15:1425-1430, 2000
19. BESARAB A, BOLTON JK, BROWNE JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339(9):584-590, 1998